Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 6:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 165 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Red blood cell transfusion Clear all
Completed No phase listed Observational

RBC Irradiation, Anemia and Gut Injury

NCT02741648
View directory record Official record
Conditions
Anemia, Necrotizing Enterocolitis
Interventions
Near Infrared Spectroscopy, Non-invasive Image-based Anemia Assessment
Device · Other
Lead sponsor
Emory University
Other
Eligibility
1 Day to 5 Days
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 20, 2026, 6:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Duration of Red Blood Cell Storage Prior to Transfusion

NCT02087514
View directory record Official record
Conditions
Iron, Blood Level Abnormal
Interventions
Blood Transfusion, Packed red blood cells
Procedure · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Sep 20, 2026, 6:34 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Comparative Analysis of Biotinylated, Irradiated and 51-Chromium Radiolabeled Red Blood Cells for Analysis of Recovery and Survival After Autologous Transfusion

NCT07446647
View directory record Official record
Conditions
Healthy Volunteer Red Blood Cell Labeling Study; Not Disease Focused
Interventions
Biotinylated Red Blood Cells (BioRBC), Irradiated Biotinylated Red Blood Cells (Irradiated BioRBC), 51 Chromium Labeled Red Blood Cells (51Cr RBC), Technetium 99m Labeled Red Blood Cells (99mTc RBC)
Biological
Lead sponsor
Jose Cancelas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Cincinnati, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 20, 2026, 6:34 PM EDT
Completed Phase 1 Interventional

Red Cell Transfusion Goals in Patients With Acute Leukemias

NCT02086773
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Acute Promyelocytic Leukemia (APL)
Interventions
Red blood cell transfusion
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Sep 20, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia

NCT03342404
View directory record Official record
Conditions
Thalassemia
Interventions
Luspatercept, Placebo, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 20, 2026, 6:34 PM EDT
Completed Phase 3 Interventional Results available

Age of Blood in Children in Pediatric Intensive Care Units

NCT01977547
View directory record Official record
Conditions
Anemia
Interventions
Short storage RBC age
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Days to 15 Years
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Sep 20, 2026, 6:34 PM EDT
Withdrawn Phase 1 Interventional

POOLED Red Blood Cells Prepared From Pooling 5 Leukoreduced, Irradiated RBC Units

NCT03056378
View directory record Official record
Conditions
Transfusion Reaction, Anemia
Interventions
Standard RBCs
Biological
Lead sponsor
New York Blood Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Sep 20, 2026, 6:34 PM EDT
Active, not recruiting Not applicable Interventional

Trial of Indication-Based Transfusion of Red Blood Cells in ECMO

NCT05405426
View directory record Official record
Conditions
Extracorporeal Membrane Oxygenation, Red Blood Cell Transfusion, Organ Failure, Multiple
Interventions
Red blood cell transfusion
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Days to 6 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 20, 2026, 6:34 PM EDT
Completed Phase 3 Interventional Results available

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence

NCT01178281
View directory record Official record
Conditions
Primary Myelofibrosis, MPN-associated Myelofibrosis
Interventions
Pomalidomide 0.5 mg, Placebo, Pomalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
17
States / cities
Scottsdale, Arizona • Los Angeles, California • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Sep 20, 2026, 6:34 PM EDT
Active, not recruiting Phase 2 Interventional

Bevacizumab In Hereditary Hemorrhagic Telangiectasia

NCT04404881
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
Bevacizumab (Avastin®)
Drug
Lead sponsor
Hanny Al-Samkari, MD
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 20, 2026, 6:34 PM EDT
Completed No phase listed Observational

Transfer of GPI-Linked Proteins to Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT00039923
View directory record Official record
Conditions
Paroxysmal Hemoglobinuria
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 20, 2026, 6:34 PM EDT
Completed Phase 3 Interventional Results available

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

NCT00235391
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Myelofibrosis
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
27
States / cities
Little Rock, Arkansas • Berkeley, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Sep 20, 2026, 6:34 PM EDT
Completed Phase 2 Interventional Results available

Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3)

NCT02280655
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Storage-aged red blood cells (saRBCs) units, Fresh red blood cells units
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced Sep 20, 2026, 6:34 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia

NCT02604433
View directory record Official record
Conditions
Erythrocyte Transfusion, Beta-Thalassemia
Interventions
Luspatercept, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 20, 2026, 6:34 PM EDT
Completed Phase 4 Interventional Results available

Early Whole Blood in Patients Requiring Transfusion After Major Trauma

NCT01227005
View directory record Official record
Conditions
Trauma/Injury Problem
Interventions
Transfusion of blood products
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 100 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2018 · Synced Sep 20, 2026, 6:34 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Siplizumab for Sickle Cell Disease Transplant

NCT06078696
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Siplizumab, Exchange Transfusion, Total Body Irradiation, Stem Cell Infusion, Cyclophosphamide 50mg, Mesna, Sirolimus Oral Tablet, Rituximab or Biosimilar
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 20, 2026, 6:34 PM EDT
Recruiting Phase 3 Interventional

Trauma Resuscitation With Low-Titer Group O Whole Blood or Products

NCT05638581
View directory record Official record
Conditions
Wounds and Injuries, Shock, Hemorrhagic
Interventions
LTOWB, Components
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
15 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 20, 2026, 6:34 PM EDT
Recruiting Phase 2 Interventional

A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

NCT04419649
View directory record Official record
Conditions
Myelodysplastic Syndromes, Cytopenia
Interventions
Elritercept
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
11
States / cities
Hot Springs, Arkansas • Duarte, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 20, 2026, 6:34 PM EDT
Completed Early Phase 1 Interventional Results available

RHD Genotype Matched Red Cells for Anti-D

NCT04156906
View directory record Official record
Conditions
Sickle Cell Disease, Anti-D Antibodies
Interventions
D+ RH genotype matched red cell units for transfusion
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 20, 2026, 6:34 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

NCT00840827
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
lenalidomide, cyclosporine A
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 20, 2026, 6:34 PM EDT
Terminated Phase 4 Interventional Results available

Physiologic Effects of RBC Transfusion

NCT02566577
View directory record Official record
Conditions
Red Blood Cell Transfusion
Interventions
Fresh red blood cell (RBC) transfusion, Storage-aged red blood cell (RBC) transfusion, Electronic infusion pump
Biological · Device
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Sep 20, 2026, 6:34 PM EDT
Terminated Phase 1Phase 2 Interventional

Red Blood Cell Transfusion in Patients With Coronary Artery Disease (CAD)

NCT01504945
View directory record Official record
Conditions
Acute Coronary Syndrome, Anemia
Interventions
RBC transfusion, Normal saline infusion
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 20, 2026, 6:34 PM EDT
Suspended Phase 1 Interventional

Packed Red Blood Cell Transfusion During Cardiac Arrest

NCT06462027
View directory record Official record
Conditions
Cardiac Arrest
Interventions
Packed Red Blood Cells (1 unit), Packed Red Blood Cells (2 units), Saline
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 20, 2026, 6:34 PM EDT
Recruiting Phase 3 Interventional

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT07422480
View directory record Official record
Conditions
Myelodysplastic Syndrome, Anemia
Interventions
Elritercept, Epoetin Alfa
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
31
States / cities
Gilbert, Arizona • Duarte, California • Santa Rosa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 20, 2026, 6:34 PM EDT